Maxigen BiotechTPE:1783 -0.51%87 OCF Yield % is 8.49 as of Jul. 02, 2026, which is 81% above its 10-year median of 4.68. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.08 (Significantly Undervalued). Among 855 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 81.29% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Maxigen Biotech's OCF Yield % or its related term are showing as below:
TPE:1783'
s OCF Yield % Range Over the Past 10 Years
Min: -3.33 Med: 4.68 Max: 11.78
Current: 8.49
During the past 13 years, the highest OCF Yield % of Maxigen Biotech was 11.78%. The lowest was -3.33%. And the median was 4.68%.
TPE:1783's OCF Yield % is ranked better than 81.29% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.71
vs TPE:1783: 8.49
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Maxigen Biotech OCF Yield % Related Terms
Maxigen Biotech OCF Yield % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: OCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a OCF Yield % of 8.49 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Maxigen Biotech and its competitors. This is 81% above median its historical median of 4.68. According to the industry distribution chart, Maxigen Biotech ranks #160 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 18.7%.
Is Maxigen Biotech's OCF Yield % too high?
Maxigen Biotech's current OCF Yield % of 8.49 is 81% above median its 10-year median of 4.68. The Medical Devices & Instruments industry median OCF Yield % is 1.71. Maxigen Biotech's value of 8.49 is 396.5% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #160 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's OCF Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #160 out of 855 companies for OCF Yield %. This places Maxigen Biotech in the top 19% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.71. Maxigen Biotech's value of 8.49 is 396.5% above this benchmark. While the company's 10-year median is 4.68 vs. the industry median of 1.71, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.71, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current OCF Yield % of 8.49 is 396.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current OCF Yield % is 8.49, which is 81% above median its own 10-year median of 4.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.08, compared to a current price of NT$38.85 — trading 36.4% below its estimated fair value. The current OCF Yield % is 8.49, which is 81% above median its 10-year median of 4.68 and 396.5% above the Medical Devices & Instruments industry median of 1.71. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current OCF Yield % is 8.49 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.85 is trading 36.4% below its estimated GF Value™ of NT$61.08.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
OCF Yield %: 8.49 (81% above median its 10-year median of 4.68)
GF Value™: NT$61.08 vs. price of NT$38.85 (36.4% below fair value)
Industry Position: 396.5% above the Medical Devices & Instruments median (#160 of 855)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
